Pathway for Biosimilars Act gives agencies 'flexibility'

Share this article:
Rep. Anna Eshoo (D-CA) and Rep. Joe Barton (R-TX) have introduced legislation that would create a regulatory pathway for the FDA to approve follow-on or generic biologics. Their “Pathway for Biosimilars Act” would give the agency “flexibility” to determine the level of clinical testing needed and allow innovators 12 years of data exclusivity.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions